10. The pharmaceutical composition according to any one of claims 1-9 for use in the treatment of at least one disease responsive to FGFR1 inhibition, and/or at least one disease responsive to KDR inhibition.

11. Use of the pharmaceutical composition according to any one of claims 1-9 in the manufacture of a medicament for treatment of at least one disease responsive to FGFR1 inhibition, and/or at least one disease responsive to KDR inhibition.